Safety
ADVERSE REACTIONS, ADVERSE EVENT, ADVERSE REACTION
At the time of writing this report, no serious adverse event or adverse event of special interest was observed. Within 7 days after booster vaccination, 31 participants (11.92%) in NVSI-06-09 group and 34 (13.28%) in BBIBP-CorV group reported at least one solicited adverse reaction, all of which were ranked as grade 1 or 2. The occurrence of solicited adverse reactions was low and similar between two groups (The incidence and severity of adverse reactions in NVSI-06-09 booster group compared with those in BBIBP-CorV booster group. 